IP Library Granted Patent US 11,046,638
Granted Patent B2
US 11,046,638 · App. 17/095,707 · Granted Jun 29, 2021

Processes for the preparation of zuclomiphene and intermediates thereof

Inventors: Avedis Karadeolian (Brantford, CA); Fabio E. S. Souza (Brantford, CA); Michael R. Emmett (Brantford, CA); Allan W. Rey (Brantford, CA)
Assignee: Apotex Inc.
C07C213/02B01J23/755C07C217/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,638
App. No.
17/095,707
Granted
Jun 29, 2021
Kind
B2
Abstract

The present invention provides processes for the preparation of zuclomiphene, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the carbometallation of diphenylacetylene with a compound of Formula (3) to afford either zuclomiphene or an intermediate which is converted to zuclomiphene.

Claims (34)

1. A process for the preparation of zuclomiphene (1-A):

or a salt thereof, comprising:

(i) reacting diphenylacetylene, in the presence of a nickel(II) catalyst, with a compound of Formula (3):

followed by a chlorinating agent,

wherein

A is —OCH 2 CH 2 NEt 2 or G;

M is zinc or magnesium; and

X is halide;

to provide either zuclomiphene (1-A) when A is —OCH 2 CH 2 NEt 2 or, when A is G, a compound of Formula (2-A):

wherein

G is OPG or X 1 ;

PG is an alcohol protecting group;

X 1 is halide; and

(ii) when A is G, converting the G group in the compound of Formula (2-A) to the —OCH 2 CH 2 NEt 2 group of zuclomiphene (1-A).

2. The process of claim 1 , wherein M is magnesium and X is bromide or chloride.

3. The process of claim 2 , wherein the chlorinating agent is selected from the group consisting of chlorine, N-chlorosuccinimide, thionyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, hexachloroethane, and 1,3-dichloro-5,5-dimethylhydantoin.

4. The process of claim 3 , wherein the chlorinating agent is 1,3-dichloro-5,5-dimethylhydantoin.

5. The process of claim 2 , wherein the nickel(II) catalyst is selected from the group consisting of nickel(II) chloride, nickel(II) chloride hexahydrate, nickel(II) bromide, nickel(II) chloride ethylene glycol dimethyl ether complex, nickel(II) bromide ethylene glycol dimethyl ether complex, nickel(II) acetylacetonate, and nickel(II) acetate tetrahydrate.

6. The process of claim 5 , wherein the nickel(II) catalyst is nickel(II) chloride hexahydrate.

7. The process of claim 2 , wherein the reaction of diphenylacetylene and the compound of Formula (3) is conducted in the presence of a solvent (S1) selected from the group consisting of aromatic hydrocarbons, ethers, and mixtures thereof.

8. The process of claim 2 , wherein the reaction of diphenylacetylene and the compound of Formula (3) is conducted at a temperature in the range of about 50° C. to about 80° C.

9. The process of claim 2 , wherein the compound of Formula (2-A) is a compound of Formula (2-A1):

and the process of converting the compound of Formula (2-A) to zuclomiphene (1-A), or a salt thereof, comprises reacting the compound of Formula (2-A1) with Et 2 NCH 2 CH 2 OH.

10. The process of claim 9 , wherein the reaction of the compound of Formula (2-A1) with Et 2 NCH 2 CH 2 OH is conducted in the presence of a base (B1) that is selected from the group consisting of potassium tert-butoxide, sodium tert-butoxide, sodium hydride, and potassium hydride and a solvent (S3) that is an ether.

11. The process of claim 10 , wherein the solvent (S3) is selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, and 1,4-dioxane and the base (B1) is potassium tert-butoxide.

12. The process of claim 2 , wherein the compound of Formula (2-A) is a compound of Formula (2-A3):

wherein

PG is an alcohol protecting group,

and the process of converting the compound of Formula (2-A) to zuclomiphene (1-A), or a salt thereof, comprises deprotecting the compound of Formula (2-A3) and alkylating the resulting intermediate with a compound of Formula Et 2 NCH 2 CH 2 LG, or a salt thereof, wherein LG is a leaving group.

13. The process of claim 12 , wherein PG is methyl.

14. The process of claim 13 , wherein the deprotecting is conducted in the presence of boron tribromide.

15. The process of claim 14 , wherein LG is chloride.

16. The process of claim 1 , wherein the isomeric purity of zuclomiphene (1-A), or a salt thereof, that is produced is at least about 80%.

17. The process of claim 1 , wherein the zuclomiphene (1-A) that is produced is further converted to zuclomiphene (1-A) citrate.

Assignments (2)
SECURITY INTEREST Recorded Apr 15, 2023
From: APOTEX INC.
To: THE BANK OF NOVA SCOTIA
Reel/Frame 063364/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: KARADEOLIAN, AVEDIS; SOUZA, FABIO E. S.; EMMETT, MICHAEL R.; REY, ALLAN W.
To: APOTEX INC.
Reel/Frame 055260/0926 →
Continuity (2)
Provisional Application 62935107 · Nov 14, 2019
Related Publication 20210147337A1 · May 20, 2021